From:ww.forbes.com/feeds/ap/2005/02/28/ap1852619.html* * * * Elan chief executive Kelly Martin told reporters in Ireland, where the company is based, that the drug has been withdrawn as a precaution and that the companies hoped to resume marketing of Tysabri later this year.* * * *
That seemed to be the senitment in BIIB CC also..better to err on side of caution.
ELN is massively oversold and will regain some this afternoon. Next week we'll trade around $12. Look into the financials as well as other promising ELN drugs. The returns from here are compelling.